Elastase-mediated phosphatidylserine receptor cleavage impairs apoptotic cell clearance in cystic fibrosis and bronchiectasis

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation

Published Version
doi:10.1172/JCI200213572

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:32683886

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Introduction
Resolution of acute inflammation is normally accomplished by removal of dying, apoptotic inflammatory cells (1, 2). In the cystic fibrosis (CF) lung, inflammation is persistent and necrotic cells accumulate in the airway (3), suggesting that normal apoptotic cell removal mechanisms may be impaired. Recognition of apoptotic cells promotes the resolution of inflammation in a number of ways. Phagocytosis of apoptotic cells leads to their efficient removal before disruption of the plasma membranes and spillage of potentially harmful intracellular contents. Removal of apoptotic cells also actively suppresses ongoing inflammation by the production of anti-inflammatory signals such as TGF-β (4). These anti-inflammatory signals inhibit inflammatory mediator production and subsequently enhance resolution of the response (4, 5).

Apoptotic cells target themselves for recognition and uptake into phagocytes by expressing surface ligands, in particular phosphatidylserine (PS) (6, 7). A variety of receptors are involved in the removal process, especially a recently cloned specific receptor for PS (8). Other recognition molecules include CD36 (9), other scavenger receptors (10), CD14 (11), a variety of integrins (12, 13), as well as soluble bridging molecules such as thrombospondin (9), the collectins (14, 15), or C1q (15, 16). However, the requirement for PS expression (6, 7) and a dominant role for the PS receptor (8) suggest that this interaction plays a major role in the recognition and uptake of apoptotic cells. The PS receptor also appears critical in the anti-inflammatory effects of apoptotic cell recognition and initiation of the TGF-β production, both in vitro (4, 5) and in vivo (17).

The clearance of dying apoptotic cells from developing tissues or sites of inflammation is normally a
highly efficient process. Examples include the removal of apoptotic cells from the limb during embryonic development, shrinkage of the tadpole tail during metamorphosis, and loss of apoptotic thymocytes during normal or steroid-induced involution of the thymus (1). Despite significant ongoing apoptosis, remarkably few apoptotic cells can be detected in these tissues at any point in time due to their rapid clearance (1). In the human respiratory tract, cell removal during resolution of inflammation is just as efficient. During the acute respiratory distress syndrome neutrophils (PMNs) migrate into the lung in large numbers reaching $7.4 \times 10^6/ml$ (18); however, only 1.6% of these are apoptotic (18). Similarly, in community-acquired pneumonia PMNs reach $1.1 \times 10^6/ml$ (19), yet only 0.3% are apoptotic (20). This suggests that extrusion of inflammatory cells into the airway lumen, by itself, is not a sufficient cause for the accumulation of apoptotic cells.

Accordingly, detection of significant numbers of apoptotic cells in an inflammatory site, such as the airways of patients with CF and non-CF bronchiectasis, may suggest dysregulated clearance. Abnormal removal of apoptotic inflammatory cells in CF could, in turn, facilitate the persistence or enhancement of airway inflammation by (a) allowing the development of postapoptotic necrosis with the consequent release of proinflammatory materials and by (b) altering mechanisms that would normally actively suppress proinflammatory mediator production.

In CF airways, inflammation begins during the neonatal period, extends through adulthood, and is associated with chronic bacterial infection, increased IL-8, TNF-α, PMN influx, and release of PMN proteases (21–23). Evidence of airway inflammation has been demonstrated in infants as young as 4 weeks, and a significant proportion of infants under 1 year of age have airway inflammation in the absence of infection (21). Regardless of the initiating stimulus, the result is massive influx of inflammatory cells into the airways, where they die, liberate intracellular proteases that overwhelm antiprotease defenses (23), and leave proteases unopposed to injure airways and impair host defense. This complex inflammatory milieu in the CF airway may be considered an extreme manifestation of a pattern of protease/antiprotease imbalance that appears to be representative of a variety of chronic airway inflammatory diseases, such as bronchiectasis (24), chronic bronchitis (25, 26), asthma (26), and α1-antitrypsin deficiency (27).

We sought to determine whether apoptotic cells accumulate excessively in the airways of CF patients compared with other diseases characterized by chronic airway inflammation and find that airway apoptotic cells are markedly increased in patients with CF and non-CF bronchiectasis. We further show an impairment of apoptotic cell engulfment induced by fluid from such airways and demonstrate that this may be due to the cleavage of the PS receptor from phagocytic cells by active elastase.

### Methods

**Materials.** Purified human elastase (21 U/mg protein), human cathepsin G (3 U/mg protein), and the specific elastase inhibitor, MeOSuc-Ala-Ala-Pro-Val-CMK (NEI), were obtained from Calbiochem-Novabiochem Corp. (San Diego, California, USA). The specific cathepsin G inhibitor (CGI), Z-Gly-Leu-Phe-CMK, was obtained from Enzyme Systems Products Inc. (Livermore, California, USA). DMP777, a specific inhibitor of PMN elastase, and its inactive enantomer, SJ527, were kindly provided by DuPont Pharmaceuticals Co. (Wilmington, Delaware, USA). Human proteinase 3 (13.5 U/mg protein) was obtained from Elastin Products (Owensville, Missouri, USA). Mouse monoclonal anti-PS receptor IgM was prepared in this laboratory as described previously (8). Ab’s obtained from PharMingen (San Diego, California, USA) included mouse monoclonal anti-human CD36 IgM, mouse monoclonal anti-human CD45 IgG, mouse monoclonal anti-human CD32 (FcγRII) IgG, mouse monoclonal anti-keyhole limpet hemocyanin IgM, and mouse IgG. Ab’s obtained from Jackson ImmunoResearch Laboratories Inc. (West Grove, Pennsylvania, USA) included rabbit anti-mouse IgG, Cy-3 goat IgG anti-mouse IgM, and Cy-3 goat IgG anti-mouse IgG. Human α1-antitrypsin was obtained from Sigma Chemical Co. (St. Louis, Missouri, USA).

**Human subjects.** The study was approved by, and performed in accordance with, the ethical standards of our institutional review boards on human experimentation. Written informed consent was obtained from each subject. Chronic bronchitis patients were current smokers or had smoked previously and had sputum production for at least 3 months during 2 successive years. Bronchiectasis was documented in patients using high-resolution computed tomography, and none were heterozygous, or homozygous, for 86 known CF mutations (Genzyme Corp., Framingham, Massachusetts, USA). Bronchiectasis patients included four with a history of Mycobacterium avium intracellulare, one with allergic bronchopulmonary aspergillosis, and one with idiopathic bronchiectasis. All CF patients were homozygous for the ΔF508 CF transmembrane regulator mutation, except one who was a compound heterozygote for ΔF508/R553X.

Sputum was collected from patients in all three groups during a clinical exacerbation defined by increased cough and sputum production. Sputum cultures were taken to identify bacterial or fungal pathogens. All patients had spirometry within a month of the study.

**Assessment of sputum apoptotic cells.** First morning sputum was collected on ice and processed immediately with Sputolysin (Caldon Biotech Inc., Carlsbad, California, USA), centrifuged onto slides (Cytospin; Shandon Inc., Pittsburgh, Pennsylvania, USA), stained with modified Wright’s Giemsa (Fisher Scientific, Pittsburgh, Pennsylvania, USA), and analyzed blindly for apoptosis using nuclear condensation or a modified TUNEL assay per the manufacturer’s recommendations (Promega Corp., Madison, Wisconsin, USA). Sputum alveolar macrophages (AMs) were also examined.
Preparation of CF and non-CF bronchiectasis sol. Sol was made from CF or non-CF bronchiectasis sputum using a protocol described previously (28). First morning sputa were collected on ice from hospitalized patients and fractionated immediately into aqueous sol and gel fractions by ultracentrifugation (50,000 g for 90 minutes). CF sol was pooled from six patients, and non-CF bronchiectasis sol was pooled from three patients. Elastase and cathepsin G activity were measured using methods that depended on elastase cleavage of MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide (Calbiochem-Novabiochem Corp.) and cathepsin G cleavage of Suc-Ala-Ala-Pro-Phe-p-nitroanilide (Calbiochem-Novabiochem Corp.), as described previously (28).

Cell isolation and culture. Human monocyte-derived macrophages (HMDMs) and PMNs were isolated using Percoll gradient centrifugation, as described previously (28). Monocytes were plated in 24-well tissue culture plates and fractionated immediately into aqueous sol and gel fractions by ultracentrifugation (50,000 g for 90 minutes). CF sol was pooled from six patients, and non-CF bronchiectasis sol was pooled from three patients. Elastase and cathepsin G activity were measured using methods that depended on elastase cleavage of MeO-Suc-Ala-Ala-Pro-Val-p-nitroanilide (Calbiochem-Novabiochem Corp.) and cathepsin G cleavage of Suc-Ala-Ala-Pro-Phe-p-nitroanilide (Calbiochem-Novabiochem Corp.), as described previously (28).

HMDMs were greater than 99% viable in the presence and absence of CF sol, assessed by trypan blue exclusion. Fresh AMs were cocultured with apoptotic PMNs in a similar fashion, except experiments were conducted in 96-well plates.

Reconstitution of plasma membrane outer leaflet with PS. PLB985 cell membranes were reconstituted with lipids using liposomes containing a 50:50 molar ratio of PS to phosphatidylcholine (PC) (both from Avanti Polar Lipids Inc., Alabaster, Alabama, USA), or 100% PC, as previously described, and used immediately (7).

FACS analysis. HMDMs or AMs were suspended in HBSS containing 2% FBS (Gemini Bio Products). HMDMs or AMs (10⁶) were incubated with 1 µg of primary Ab on ice for 30 minutes, washed twice, then incubated with secondary Ab (1:50 dilution) on ice for 30 minutes. Washed macrophages were analyzed on a FACScan cytometer using PCLysys software (Becton Dickinson and Co.).

Statistics. The means were analyzed using ANOVA for multiple comparisons; when ANOVA indicated significance, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all comparisons, the Tukey-Kramer honestly significant difference (HSD) test for all pairs was used to compare groups (Table 1, Figure 1, e and f, and Figure 2, a and c). For all
other experiments in which an internal control was present, the Dunnett method was used. All data were analyzed using JMP (version 3) Statistical Software for the Macintosh (SAS Institute Inc., Cary, North Carolina, USA) and are presented plus or minus SEM.

Results

Study patients. Patient demographics are summarized in Table 1. CF patients were younger, had less expiratory airflow obstruction, as measured by the forced expiratory volume in 1 second (FEV1), and were more likely to be colonized with mucoid Pseudomonas aeruginosa. Bronchiectasis patients were more likely to have been infected with M. avium intracellulare.

Sputum apoptotic cells are increased in patients with CF and non-CF bronchiectasis. Apoptotic cells were quantitated in sputum by nuclear condensation (Figure 1a) and by TUNEL staining. Transmission electron microscopy demonstrated the presence of early apoptotic, late apoptotic, and necrotic PMNs in CF sputum (Figure 1, b–d). Sputum apoptotic cells were present in all patient groups (Figure 1e). Assessed by nuclear condensation, apoptotic cells were greater in CF and non-CF bronchiectasis compared with chronic bronchitis patients. TUNEL staining confirmed these results; however, the difference between bronchiectasis and chronic bronchitis did not reach significance. Sputum samples were also examined for AM ingestion of apoptotic cells (Figure 1f). CF AMs contained fewer apoptotic bodies than those from patients with chronic bronchitis. These data establish that apoptotic cells are present in the airways of patients with CF, non-CF bronchiectasis, and chronic bronchitis during clinical exacerbations, but the relative abundance of apoptotic cells depends upon the underlying disease. Furthermore, clearance of apoptotic cells by CF AMs appears to be defective.

CF sol impairs macrophage phagocytosis of apoptotic cells in an elastase-dependent manner. Experiments were conducted to test whether CF airway fluid impaired the ability of HMDMs to ingest apoptotic cells (Figure 2a). These experiments demonstrated that ingestion of apoptotic Jurkat cells by HMDMs, but not IgG-opsonized or viable Jurkat cells, was inhibited by 10% CF sol. Serine proteases, present in the airway secretions of patients with CF and non-CF bronchiectasis, were considered as possible contributors to the sol-mediated delay in apoptotic cell clearance. CF sol contained 3 U/ml of PMN elastase and 28 mU/ml of cathepsin G. Non-CF bronchiectasis sol contained 10 U/ml of PMN elastase and 77 mU/ml of cathepsin G. Two specific inhibitors of PMN elastase, DMP777 (20 µM) and NEI (100 µM), completely and specifically inhibited elastase activity in 10% CF and bronchiectasis sol (data not shown). In addition, a specific inhibitor of cathepsin G, CGI (10 µM), completely and specifically inhibited cathepsin G activity in both sol preparations (data not shown).

The specific PMN elastase inhibitor, DMP777, was used to test whether elastase contributed to the inhibitory effect of CF sol (Figure 2b). HMDMs cultured with apoptotic Jurkat cells, in the presence of CF sol, ingested fewer apoptotic cells, but not in the presence of DMP777. Neither the inactive enantiomer, SJ527, nor the methylcellulose vehicle prevented the CF sol-mediated decrease in apoptotic cell ingestion. Similarly, pretreatment of HMDMs with 10% CF sol

Figure 1

Clearance of apoptotic cells is defective in CF airways. (a) Wright’s Giemsa stain of CF sputum (×100) showing apoptotic cells with condensed nuclei (open arrow) and normal PMNs (arrows). (b–d) Transmission electron micrograph of sputum from a CF patient (×6,300; bars: 1 µm) demonstrating early apoptosis (b), late apoptosis (c), and postapoptotic necrosis (d). Arrows (b and c) indicate condensed apoptotic nuclei. Arrowheads (d) show loss of membrane integrity during necrosis. (e) Sputa from CF or bronchiectasis patients contain more apoptotic cells compared with chronic bronchitis. The percentage of apoptotic cells (by nuclear condensation and TUNEL staining) ± SEM is shown for six patients per group. *Apoptosis by nuclear condensation is significantly different from chronic bronchitis (P < 0.05). **Apoptosis by TUNEL staining is significantly different from chronic bronchitis (P < 0.05). (f) Airway macrophages from CF patients ingest fewer apoptotic cells. The mean phagocytic index of sputum macrophages ± SEM is shown for six patients per group. *Phagocytic index is significantly different from chronic bronchitis (P < 0.05).
decreased the phagocytic index during coculture with apoptotic Jurkat cells (8.5 ± 3.0) compared with control (22.5 ± 5.5), but not following preincubation of sol with the natural serine protease inhibitor, α1-antitrypsin, at 100 µg/ml (15.8 ± 0.3) or 1,000 µg/ml (16.5 ± 2.5).

Experiments were performed to establish whether the effect of CF sol on apoptotic cell phagocytosis was due to action on the phagocyte, apoptotic cell, or both (Figure 2c). These data showed that CF sol decreased ingestion of apoptotic cells following pretreatment of HMDMs, apoptotic Jurkat cells, or both. DMP777 partially prevented CF sol from impairing phagocytosis for all three groups tested, but in the case of apoptotic Jurkat cells statistical significance was not reached.

We also tested the possibility that CF HMDMs were intrinsically defective at ingestion of apoptotic cells. However, these experiments did not demonstrate any deficiency in the ability of HMDMs from CF patients to ingest apoptotic cells compared with normal HMDMs (data not shown).

These data suggest that CF sol diminishes macrophage ingestion of apoptotic cells, but not IgG-opsonized cells.
through an elastase-dependent mechanism. Furthermore, CF sol appears to reduce phagocytosis of apoptotic cells by actions on both the macrophage and the target apoptotic cell.

**PMN elastase and cathepsin G impair macrophage phagocytosis of apoptotic but not IgG-opsonized cells.** Three serine proteases with known activity in airway secretions of CF and non-CF bronchiectasis (elastase, cathepsin G, and proteinase 3) were evaluated to determine their effect on HMDM ingestion of apoptotic Jurkat cells (Figure 3a). Elastase (1 µM, 0.6 U/ml) and cathepsin G (1 µM, 70 µU/ml) decreased HMDM ingestion of apoptotic Jurkat cells compared with control. In contrast, proteinase 3 had no effect in the concentrations tested. In addition, 1 µM elastase (13.0 ± 2.5) and 1 µM cathepsin G (9.8 ± 1.8) had no effect on the ability of HMDMs to ingest IgG-opsonized Jurkat cells, compared with control (9.8 ± 2.3).

In the airway the AM is the professional phagocyte that is most likely to be involved with removal of apoptotic inflammatory cells. Therefore, we sought to test whether serine proteases interfere with human AM ingestion of apoptotic PMNs (Figure 3b). AMs were isolated from normal subjects and were cocultured with apoptotic human PMNs. Elastase (1 µM, 0.6 U/ml) and cathepsin G (1 µM, 70 µU/ml) inhibited human AM uptake of apoptotic human PMNs, and this effect was reversed by the corresponding specific inhibitors. These results confirmed that human AMs ingest apoptotic PMNs and that this uptake is inhibited by either PMN elastase or cathepsin G.

Together, these data establish that elastase and cathepsin G interfere with phagocytosis of apoptotic cells by HMDMs and AMs.

**Sol from CF and non-CF bronchiectasis inhibits human AM ingestion of apoptotic PMNs in an elastase-dependent manner.** Experiments were conducted to determine whether sol-derived serine proteases disrupt the ability of AMs to remove apoptotic PMNs. These experiments demonstrated that sol from CF (Figure 4a) and non-CF bronchiectasis patients (Figure 4b) inhibited human AM clearance of apoptotic human PMNs and that this sol effect was prevented by two specific inhibitors of elastase. In contrast, a specific cathepsin G inhibitor did not, by itself, prevent the effect of sol on apoptotic cell removal. These results strongly suggest that elastase, present in the airways of patients with CF or non-CF bronchiectasis, has the capacity to interfere with removal of apoptotic PMNs by AMs.

**CF sol cleaves the PS receptor in an elastase-dependent manner.** Flow cytometry was used to test the effect of CF sol on macrophage receptors involved with phagocytosis of apoptotic cells (Figure 5). HMDMs were used in these experiments; however, all receptors tested were also present on human AMs (data not shown). CF sol did not alter staining for CD32 (FcγRII), CD36, or vitronectin receptor (data not shown). In contrast, CF sol decreased staining for the PS receptor, but not in the presence of the elastase inhibitor, DMP777. These data suggest that CF sol elastase may interfere with phagocytosis of apoptotic cells through degradation of the PS receptor. To further test this hypothesis, HMDMs were incubated with elastase, cathepsin G, or proteinase 3, and staining for the PS receptor and CD36 was assessed (Figure 6). Only elastase cleaved the PS receptor at the concentrations tested.

**CF sol elastase impairs PS receptor–mediated phagocytosis of apoptotic cells.** To test the effect of CF sol on PS receptor–mediated phagocytosis, the PLB985 myelomonocytic cell line was used. PLB985 cells undergo the typical nuclear morphologic and biochemical changes characteristic of apoptosis (7). However, undifferentiated PLB985 cells do not externalize PS from the inner to the outer membrane leaflet during apoptosis (7). Consequently, they do not interact with PS receptor on the surface of the macrophage to drive ingestion. Reconstitution of the plasma membrane outer leaflet with PS, but not PC, increases the ability of macrophages to recognize and ingest apoptotic PLB985 cells through specific interaction with the PS receptor (7).
The effect of CF sol on phagocytosis of apoptotic cells through the PS receptor was tested using viable and apoptotic PLB985 cells (Figure 7). In some PLB985 cells, membrane PS, or control PC, was reconstituted prior to coculture. Reconstitution of membrane PS, but not PC, increased HMDM ingestion of apoptotic PLB985 cells, compared with viable PLB985 cells. In contrast, PS reconstitution of apoptotic cells did not augment their engulfment by CF sol-pretreated HMDMs, except in the presence of DMP777. Therefore, these results imply that degradation of PS receptor by CF sol elastase directly impairs apoptotic cell clearance by HMDMs.

Discussion

Three human diseases characterized by chronic airway inflammation were evaluated to determine whether airway clearance of apoptotic cells might be abnormal. Our data indicate that apoptotic cells are present in the sputa from all three groups studied, but are much more abundant in patients with CF and non-CF bronchiectasis, compared with those with chronic bronchitis. A variety of potential mechanisms may contribute to accumulation of apoptotic inflammatory cells in these circumstances. However, data presented here suggest that airway elastase inhibits apoptotic cell clearance through direct action on macrophage PS receptors. The finding of a large reservoir of uncleared, dying inflammatory cells may have a significant impact on ongoing airway inflammation.

Increased apoptotic cells in the airways of patients with CF and non-CF bronchiectasis suggest that the normal kinetics of apoptotic cell clearance is impaired, since in other PMN-dominated inflammatory pulmonary diseases efficient clearance results in very low numbers of apoptotic cells (18, 20). The airway PMN burden in the acute respiratory distress syndrome (18) and community-acquired pneumonia (19) is similar to that found in clinically stable CF patients ($1.9 \times 10^5$/ml) and in CF patients with clinical exacerbations ($1.3 \times 10^6$/ml) (29). However, in
contrast to the acute respiratory distress syndrome and community-acquired pneumonia, where less than 2% of lavage cells are reported to be apoptotic (18, 20), we found that more than 25% of inflammatory cells in CF sputum were apoptotic, 19% were apoptotic in bronchiectasis, and 3% were apoptotic in chronic bronchitis. This observation suggests that factors unique to CF, bronchiectasis, and possibly chronic bronchitis, may impair the normal apoptotic cell clearance mechanisms.

Since CF and non-CF bronchiectasis airway lining fluid significantly blocked uptake of apoptotic cells into macrophages, inhibitory materials in these airways were considered prime candidates for the effect. However, alternate explanations for apoptotic cell accumulation abound and should be considered. (a) We do not believe that the observed increase in apoptotic inflammatory cells is primarily a function of accelerated apoptosis. We found that peripheral blood PMNs from CF patients were not defective at spontaneous or ultraviolet-induced apoptosis in vitro, measured by morphology and PS expression (data not shown). The local airway environment (e.g., hyperosmolarity) could increase the rate of PMN apoptosis (30). However, available evidence strongly suggests that massive apoptosis can be cleared expediently using normal clearance mechanisms (1). Therefore, accelerated apoptosis by any means seems unlikely to account, solely, for the observed accumulation of apoptotic cells. (b) Entrapment of apoptotic cells within airway mucus and/or altered clearance by an impaired mucociliary escalator may well contribute to decreased clearance. However, biopsies of CF airways have demonstrated the presence of apoptotic cells in the airway walls, suggesting that these factors are not necessary for apoptotic cells to accumulate (31, 32). (c) Since most cell types in the body, including epithelial cells (8, 33), can ingest apoptotic cells, there may be defects in clearance at the level of the airway epithelium related to altered CF transmembrane regulator function. This might be especially relevant to early inflammation in CF. However, by the time inflammatory processes have become persistent, much of the clearance is more likely due to alveolar macrophages. Our studies of monocyte-derived macrophages from individuals with CF showed no intrinsic abnormalities in apoptotic cell engulfment (data not shown). (d) Finally, observed decreases in the lung collectins, such as surfactant protein A and surfactant protein D (34), may also contribute to poor apoptotic cell clearance, since collectins have been implicated in apoptotic cell removal (14).

The experiments described herein suggest that the airway lining fluid contains proteases that are capable of inhibiting apoptotic cell clearance, in particular elastase and cathepsin G. A variety of proteases are present in CF airway lining fluid, including elastase (23, 28, 35), cathepsin G (28, 36), proteinase 3 (37), bacterial proteases, such as Pseudomonas elastase (38), and metalloproteinases (39). While any one of these proteases potentially may interfere with apoptotic cell phagocytosis, we tested the PMN serine proteases since they are the most abundant. These studies demonstrated that CF and non-CF bronchiectasis sol contained elastase and cathepsin G in high concentrations, similar to those measured by others (28, 35). However, CF and non-CF bronchiectasis sol only impaired the ability of macrophages to ingest apoptotic cells in an elastasedependent manner. When tested individually, purified elastase and cathepsin G both inhibited macrophage uptake of apoptotic cells, whereas proteinase 3 did not. This observed difference in the effectiveness of sol-derived cathepsin G versus purified cathepsin G can likely be explained by the lower activity of cathepsin G found in 10% CF sol (2.8 mU/ml) and 10% non-CF bronchiectasis sol (7.7 mU/ml) compared with the activity of purified cathepsin G (70 mU/ml) that was necessary to inhibit apoptotic cell uptake. In contrast, the concentration of purified elastase (0.6 U/ml) necessary to inhibit apoptotic cell uptake was similar to that found in 10% CF sol (0.3 U/ml) and 10% non-CF bronchiectasis sol (1.0 U/ml). While we feel that the primary effect of sol is on the macrophage, our data also establishes that CF sol disrupts clearance by acting directly on the apoptotic cell. Apoptotic cell targets for this CF sol effect remain obscure; however, possibilities include protease cleavage of glycoprotein ligands or direct blockade of externalized PS. This effect of sol proteases is consistent with our current knowledge of the protease/antiprotease imbalance that exists in CF and non-CF bronchiectasis airways, where proteases are present in excess of their major inhibitors (23, 24).
Since protease/antiprotease imbalance is also a feature of chronic bronchitis (25), we would anticipate that chronic bronchitis sol would also impair clearance of apoptotic cells, but perhaps to a lesser extent than CF or non-CF bronchiectasis sol.

Unopposed airway proteases have been shown to inflict significant damage to host defense by injuring bronchial epithelial cells, destroying extracellular matrix components, cleaving immunoglobulin, complement, and fibronectin (23). Serine proteases may also cleave cell surface molecules and impair a variety of cell functions including phagocytosis. For example, elastase inhibits PMN phagocytosis of *P. aeruginosa* by cleaving both CR1 and C3bi, creating an “opsonin receptor mismatch” (40). Elastase also cleaves cell surface antigens (CD4 and CD8), causing impaired T lymphocyte–mediated cytotoxicity (41), and cathepsin G degrades CD14 on monocytes (42). Our data suggest that elastase in CF and non-CF bronchiectasis sol interferes with phagocytosis through cleavage of macrophage surface PS receptor. The PS receptor is a recently cloned, small, transmembrane phagocyte receptor, present on HMDMs (8, 43) and AMs (data not shown), that drives ingestion of apoptotic cells through stereospecific recognition of PS on the outer surface of apoptotic cells. It possesses potential elastase cleavage sites near the transmembrane domain that would result in loss of the putative PS-binding region of the molecule (8). The mechanism by which cathepsin G interferes with apoptotic cell ingestion remains unknown; however, cleavage of CD14, a receptor known to be involved with apoptotic cell removal, is one possibility. Alternatively, the PS receptor may be cleaved by cathepsin G, but cleavage may not be detected by the techniques used.

Since removal of dying inflammatory cells is an integral step in the resolution of inflammation, failure of this process may have proinflammatory consequences in the airways of patients with CF and non-CF bronchiectasis. Recognition of apoptotic cells by phagocytes through the PS receptor is actively anti-inflammatory, inducing TGF-β, prostaglandin E2 (4), and under some circumstances, IL-10 (5); these may act in an autocrine/paracrine manner to suppress production of a host of proinflammatory cytokines (TNF-α), chemokines (IL-8), growth factors, and lipid mediators (4, 5), similar to inflammatory mediators that are increased in CF airways (21, 22). Cleavage of the PS receptor would be expected to block this effect. In contrast, macrophage removal of lysed PMNs is much less effective at inducing TGF-β and inhibiting inflammatory mediators, in part because of its content of elastase (44). Evidence was presented here that PMNs in CF airways were also undergoing postapoptotic necrosis. This would be expected to eventually cause release of intracellular contents with potent inflammatory potential, including the elastase proposed to participate in blockade of the apoptotic cell removal.

This concept raises a potential paradox. In the normal acute inflammatory response, early influx of PMNs might well be expected to result in some release of elastase (19, 45) (even though extracellular elastase secretion is, in fact, not a major event in PMN activation). Cleavage of the PS receptor would limit production of anti-inflammatory cytokines. Why then, do all acute inflammatory reactions not progress? It would seem likely that the key limiting factor is the availability (influx) of functional antiproteases, which in a “normal” inflammatory reaction would bring the protease balance back to normal, allow PS receptor–mediated generation of anti-inflammatory mediators, appropriate clearance of the apoptotic inflammatory cells, and resolution of the response.

These results suggest that impaired clearance of apoptotic cells in diseases characterized by protease/antiprotease imbalance contributes to the enhanced inflammatory response and may precipitate ongoing inflammation and progressive airway damage. Therefore, therapies directed toward relieving this imbalance may diminish progressive pulmonary decline by preventing accumulation of apoptotic cells, subsequent postapoptotic necrosis, and defective resolution of inflammation.

Acknowledgments

We thank G. Smith and J. Henson for technical assistance with transmission electron microscopy, D. Riches for advice and discussion, J. Nick for critical review of the manuscript, and DuPont Pharmaceuticals Co. for kindly providing DMP777. Grants from the Cystic Fibrosis Foundation (to R.W. Vandivier) and the NIH (GM-48211 and HL-60980 to P.M. Henson) supported this work.


